ESMO HIGHLIGHTS 2024 – GU ROUNDTABLE DISCUSSION: Renal Cell Carcinoma

OR
Please enter your username or email address. You will receive an email message to log in.
Chapter selection available inside video player. Click here for outline.
00:10
LBA73 Tivozanib–Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma (RCC) Following 1 or 2 Prior Therapies including an Immune Checkpoint Inhibitor (ICI) – Results of the Phase III TiNivo-2 Study
08:02
LBA75 Prospective randomised phase-II trial of Ipilimumab/Nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

Chair
Dr. Christian Kollmannsberger

Panelists
Dr. Maria Jiang
Dr. Sebastian Hotte